SOURCE: Geneart AG

January 18, 2007 05:55 ET

GENEART publishes sales and earnings forecast for 2007

REGENSBURG, GERMANY -- (MARKET WIRE) -- January 18, 2007 --


- Significant increase in sales to between EUR 12.5M and EUR 14.0M expected for 2007

- GENEART profits from continuous world wide market growth for synthetic genes

- Strong EBIT improvement planned to between EUR 2.0M and EUR 2.4M

Regensburg, January 18th 2007 - GENEART, the specialist for synthetic genes, today publishes its sales and earnings forecast for the fiscal year 2007. GENEART's business volume is expected to increase to between EUR 12.5 million and EUR 14.0 million ($16.2 million - $18.1 million), thus continuing its steady growth trend in 2007. For 2006 the company sales are expected to exceed EUR 7.7 million ($10.0 million). Preliminary results for 2006 will be published on February 9th 2007. One major reason for this expected increase in sales is the continued growth of the world market for gene synthesis. As the leading provider, GENEART strongly profits from this development, as has recently been demonstrated by a major contract from the US National Institutes of Health a few days ago.

For 2007, the EBIT improvement is predicted to be between EUR 2.0 million and EUR 2.4 million ($2.6 million - $3.1 million), and thus disproportionally strong compared to sales. Major factors for this expected profit increase will be the expanded business volume, rising scale effects and technological improvements in the gene synthesis process.

Legal Information

This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.

For further inquiries, please contact:

Bernd Merkl
GENEART AG
Josef-Engert-Str. 11
D-93053 Regensburg, Germany
Tel.: +49-(0)941-942 76 - 38
Fax: +49-(0)941-942 76 - 11
ir@geneart.com
www.geneart.com

Frank Ostermair
Haubrok Investor Relations GmbH
Maximilianstraße 45
80538 München
Tel: 089-21027-204
Fax: 089-21027-298
f.ostermair@haubrok.de
Background information:

About GENEART AG

GENEART was founded in 1999. Today, the company ranks as the leading global specialist in gene synthesis for research institutions, the pharmaceutical industry and for enterprises in biotechnology and chemistry. GENEART offers integrated product systems based on gene synthesis for the development of innovative drugs, in particular for DNA- and protein-based therapeutics and vaccines, and for the identification of improved industrial enzymes. Service offerings range from synthesizing artificial genes according to DIN EN ISO 9001:2000, via constructing gene libraries in the field of combinatorial biology, to the production and development of DNA-based active components. The team of more than 80 employees in Regensburg and with the subsidiary GENEART Inc. in Toronto/Canada reached break even in 2005. Since May 2006 GENEART AG is listed at the German Stock Exchange.

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information